T. Rowe Price Associates
AGN

T. Rowe Price Associates’s Allergan plc AGN Stock Holding History

T. Rowe Price Associates’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-721,666
Closed -$128M – 2578
2020
Q1 		$128M Sell
721,666
-1,698,878
-70% -$320M 0.02% 511
2019
Q4 		$463M Sell
2,420,544
-746,736
-24% -$135M 0.06% 317
2019
Q3 		$533M Buy
3,167,280
+368,679
+13% +$60.1M 0.08% 266
2019
Q2 		$469M Buy
2,798,601
+463,755
+20% +$64.2M 0.07% 287
2019
Q1 		$342M Buy
2,334,846
+520,129
+29% +$75.4M 0.05% 326
2018
Q4 		$243M Sell
1,814,717
-177,272
-9% -$29.1M 0.04% 383
2018
Q3 		$379M Sell
1,991,989
-330,754
-14% -$60.8M 0.06% 334
2018
Q2 		$387M Sell
2,322,743
-11,565
-0.5% -$1.86M 0.06% 313
2018
Q1 		$393M Sell
2,334,308
-252,091
-10% -$42.3M 0.06% 307
2017
Q4 		$423M Sell
2,586,399
-1,487,656
-37% -$267M 0.07% 293
2017
Q3 		$835M Sell
4,074,055
-1,416,979
-26% -$330M 0.14% 162
2017
Q2 		$1.33B Sell
5,491,034
-3,147,687
-36% -$740M 0.24% 102
2017
Q1 		$2.06B Sell
8,638,721
-660,408
-7% -$154M 0.39% 57
2016
Q4 		$1.95B Sell
9,299,129
-3,433,124
-27% -$711M 0.39% 57
2016
Q3 		$2.93B Sell
12,732,253
-3,858,522
-23% -$943M 0.59% 31
2016
Q2 		$3.83B Sell
16,590,775
-4,475,883
-21% -$1.03B 0.81% 19
2016
Q1 		$5.65B Sell
21,066,658
-627,360
-3% -$180M 1.21% 8
2015
Q4 		$6.78B Sell
21,694,018
-819,704
-4% -$244M 1.43% 6
2015
Q3 		$6.12B Buy
22,513,722
+846,972
+4% +$260M 1.36% 6
2015
Q2 		$6.57B Buy
21,666,750
+1,892,527
+10% +$564M 1.35% 4
2015
Q1 		$5.89B Buy
19,774,223
+9,136,305
+86% +$2.6B 1.22% 6
2014
Q4 		$2.74B Buy
10,637,918
+6,638,874
+166% +$1.66B 0.58% 29
2014
Q3 		$965M Buy
3,999,044
+1,297,402
+48% +$290M 0.21% 120
2014
Q2 		$603M Buy
2,701,642
+133,507
+5% +$27.6M 0.13% 195
2014
Q1 		$529M Buy
2,568,135
+1,014,414
+65% +$201M 0.12% 213
2013
Q4 		$261M Buy
1,553,721
+111,912
+8% +$17.5M 0.06% 369
2013
Q3 		$208M Buy
1,441,809
+783,578
+119% +$104M 0.05% 393
2013
Q2 		$83.1M Buy
+658,231
New +$74.5M 0.02% 628

Other funds holding AGN

AJ
Ashburton (Jersey) St Helier, Jersey $227M AUM
C
Cerebellum San Francisco, California $21.5M AUM
B
Barings Charlotte, North Carolina $5.64B AUM 18.33% 1-Year Est. Return
JJ
JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

T. Rowe Price Associates's AGN Position: Q2 2020 in Review

T. Rowe Price Associates sold out of Allergan plc (AGN) in Q2 2020, closing a stake of 721,666 shares — an estimated $128M sold.

T. Rowe Price Associates first reported a position in AGN in Q2 2013 and held it in 28 quarters. The position peaked at $6.78B in Q4 2015. 7 funds tracked by Wall St. Rank hold AGN as of Q2 2020.

  • T. Rowe Price Associates reported no remaining Allergan plc position as of Q2 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 721,666 Allergan plc shares in Q2 2020, an estimated $128M.
  • T. Rowe Price Associates first reported a position in Allergan plc in Q2 2013 and held it in 28 quarters.
  • T. Rowe Price Associates's Allergan plc position peaked at $6.78B in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Allergan plc as of Q2 2020.

Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.